Patents by Inventor Bengt Erik Haug

Bengt Erik Haug has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200323888
    Abstract: The present invention relates to compounds having the formula [Co-enzyme A or analogue thereof]-Z1-Z2-Z3-Z4, wherein Z1 is a linker, Z2 and Z3 are peptides or peptide-based moieties, and Z4 is a C-terminal group. The invention also provides pharmaceutical compositions comprising compounds of the invention, and their uses for the treatment of cancer, wound healing and nerve regeneration, inter alia.
    Type: Application
    Filed: December 19, 2018
    Publication date: October 15, 2020
    Applicant: VESTLANDETS INNOVASJONSSELSKAP AS
    Inventors: Thomas ARNESEN, Bengt Erik HAUG, Line Merethe MYKLEBUST, Havard FOYN
  • Publication number: 20160176923
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 23, 2016
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 9241968
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumor agents.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: January 26, 2016
    Assignee: Lytix Biopharma AS
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 9115169
    Abstract: The invention provides a method of treating tumors by adminstering to a human or animal patient an effective amount of a molecule of 2 to 4 amino acids or equivalent subunits in length, which incorporates a bulky and lipophilic group comprising at least 13 non-hydrogen atoms and containing no more than 2 polar functional groups, in which the bulky and lipophilic group incorporates one or more closed rings of 5 or more non-hydrogen atoms, and in which the molecule further has at least two more cationic than anionic moieties.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: August 25, 2015
    Assignee: Lytix Biopharma AS
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
  • Publication number: 20120149908
    Abstract: In a first aspect, the present invention relates to a method for the preparation of alkynylpiperidine and alkynylpiperidine derivatives. In particular, a method is provided for preparing alkynylpiperidine derivatives starting from epoxide compounds. Further, the alkynylpiperidine derivatives according to the present inventions are substituted trans-3-4-alkynylpiperidine derivatives. In another aspect, triazolylpiperidine compounds and methods for said preparation are provided. In particular, the triazolylpiperidine compounds according to the present invention are obtained by reacting an alkynylpiperidine derivatives with an organic azid, preferably, in the presence of a Cu (I) or Ru catalyst. In a preferred embodiment, 1,4-disubstituted or 1,5-disubstituted 1,2,3-triazolylpiperidine compounds are provided.
    Type: Application
    Filed: December 13, 2011
    Publication date: June 14, 2012
    Inventors: Leiv K. Sydnes, Bengt Erik Haug, Rianne Harmsen
  • Publication number: 20120108520
    Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 3, 2012
    Applicant: LYTIX BIOPHARMA AS
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
  • Publication number: 20110318364
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.
    Type: Application
    Filed: September 11, 2009
    Publication date: December 29, 2011
    Applicant: LYTIX BIOPHARMA AS
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 8048852
    Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilizing microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: November 1, 2011
    Assignee: Lytix Biopharma AS
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
  • Publication number: 20100267621
    Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.
    Type: Application
    Filed: April 20, 2007
    Publication date: October 21, 2010
    Applicant: LYTIX BIOPHARMA AS
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Oystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bohmer Strom
  • Patent number: 7232803
    Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilizing microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: June 19, 2007
    Assignee: Lytix Biopharma AS
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
  • Publication number: 20030195144
    Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipoophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.
    Type: Application
    Filed: February 27, 2003
    Publication date: October 16, 2003
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Oystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bohmer Strom